Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Allergic Reactions

Allergic Reactions

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Cross-reactivity

Cross-reactivity

Asthma: Pathogenesis and Management

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

Hypersensitivities

Hypersensitivities

Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...

Allergic Drug Reactions

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same authorSame journal

Route of Allergen Immunotherapy: A Global Look Into Physicians' Motivations.

Allergy·2026

Same author

Real-World Evaluation of AI-Assisted Readout of Skin Prick Automated Test Results.

Allergy·2026

Same author

Allergen Immunotherapy for the Treatment of Eosinophilic Esophagitis. An EAACI Task Force Systematic Review.

Clinical and translational allergy·2026

Same author

Ozone alters the allergenicity of Ambrosia artemisiifolia pollen in a dose-dependent manner.

Environment international·2026

Same author

Sustained Clinical Improvement in Birch Pollen Allergy After Two Pre-Seasonal Short Courses of Allergen-Specific Immunotherapy: A Long-Term Open-Label Extension Study.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026

Same author

TNF Pathway-Mediated Tolerogenic T-Cell Trajectory Driven by Allergen Immunotherapy.

Allergy·2026

Search research articles

Related Experiment Video

Updated: Jan 1, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Perspectives in allergen immunotherapy: 2019 and beyond.

Oliver Pfaar¹, Ioana Agache², Frédéric de Blay³

¹Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.

|December 25, 2019

Summary

Global experts convened at the 2019 FASIT workshop to discuss allergen immunotherapy (AIT) advancements. They reviewed biomarkers, AIT for asthma, and regulatory considerations, identifying future research needs.

Keywords:

allergen exposure chamber allergen immunotherapy allergic asthma biomarker clinical trials

More Related Videos

Antigenic Liposomes for Generation of Disease-specific Antibodies

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Related Experiment Videos

Last Updated: Jan 1, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Antigenic Liposomes for Generation of Disease-specific Antibodies

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Area of Science:

Allergy and Immunology
Respiratory Medicine

Background:

The 2019 Future of Allergists and Specific Immunotherapy (FASIT) workshop convened global experts.
Discussions focused on current developments in allergen immunotherapy (AIT).

Purpose of the Study:

To summarize key panel discussions from the FASIT workshop.
To identify unmet needs and propose solutions in AIT research and development.

Main Methods:

Review of current developments in allergen immunotherapy (AIT).
Expert panel discussions covering biomarkers, AIT for asthma, clinical trial design, and regulatory aspects.
Analysis of GINA and EAACI Asthma Guidelines updates relevant to AIT.

Main Results:

Key domains included biomarkers for AIT, AIT in asthma, regulatory prerequisites, and trial design optimization.
Progress and data for house dust mite SCIT, SLIT tablets, and SLIT drops were discussed.
Challenges in phase III studies and the role of Allergen Exposure Chambers (AEC) were evaluated.

Conclusions:

The workshop highlighted critical areas for AIT advancement, including biomarker discovery and optimized clinical trial strategies.
Addressing unmet needs in AIT requires collaborative efforts between academia, clinics, regulatory bodies, and industry.
Future AIT development will benefit from refined regulatory pathways and innovative research methodologies.